ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Agilent Highlights Integrated Automation Solutions at SLAS 2022

Powerful modular solutions providing deeper research insights

Agilent Technologies Inc. (NYSE: A) highlights innovative laboratory automation solutions at the SLAS2022 International Conference and Exhibition held February 5 through February 9, 2022, at the Boston Convention and Exhibition Center in Boston, Massachusetts.

Agilent modular automation solutions address a wide array of cell analysis, mass spectrometry, and genomics workflows in both development and regulated environments. Overall, sample preparation is more straightforward, more accurate, and more efficient, ensuring better reproducibility, fewer replicates, faster results, and safer data.

“Agilent’s modular automation platforms deliver powerful solutions to meet the exceptional needs of our customers,” said Sudharshana Seshadri, vice president and general manager of Agilent's Mass Spec Division. “Our consultative approach – including application-specific workflow solutions – allows researchers to focus on results and gain deeper insights that will accelerate their research and ultimately their understanding of the human condition.”

Agilent integrated automation solutions highlighted at SLAS will include the BioTek BioSpa Live Cell Analysis System. This system comprises of a BioTek Cytation C10 Confocal Imaging Reader, combining automated confocal and widefield microscopy with conventional multi-mode microplate reading, and a BioTek BioSpa 8 Automated Incubator. This product combination provides fully automated live cell imaging workflows in up to eight microplates at a time.

Other integrated automation solutions on show include Agilent’s Bravo automation portfolio, powered by compliance-enabled VWorks version 14.1. VWorks automation control software provides a single, intuitive user interface that simplifies and drives laboratory automation integration. This powerful and easy-to-use software connects diverse Agilent and BioTek devices. These include the BenchCel Workstation, an automated microplate handler; the Bravo, a flexible liquid handling platform; readers, imagers, dispensers, and washers into one cohesive, integrated system ensuring maximum throughput and optimal resource utilization.

The new AssayMAP Bravo software and large capacity cartridges enable the AssayMAP Bravo to be used more efficiently during development and in regulated environments such as QA/QC. The new software also simplifies documentation and method transfer between groups so projects can be moved quickly forward through the biologics development path.

To learn more about these innovative automation solutions, SLAS attendees are invited to visit Agilent's Exhibition Booth No. 2022 at the Boston Convention and Exhibition Center.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  233.22
+4.06 (1.77%)
AAPL  278.85
+1.30 (0.47%)
AMD  217.53
+3.29 (1.54%)
BAC  53.65
+0.66 (1.25%)
GOOG  320.12
-0.16 (-0.05%)
META  647.95
+14.34 (2.26%)
MSFT  492.01
+6.51 (1.34%)
NVDA  177.00
-3.26 (-1.81%)
ORCL  201.95
-3.01 (-1.47%)
TSLA  430.17
+3.59 (0.84%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.